...
首页> 外文期刊>Research and Reports in Tropical Medicine >Counterfeit drugs and medical devices in developing countries
【24h】

Counterfeit drugs and medical devices in developing countries

机译:发展中国家的假药和医疗器械

获取原文
           

摘要

The World Health Organization has reported that counterfeit medicines potentially make up more than 50% of the global drug market, with a significant proportion of these fake products being encountered in developing countries. This occurrence is attributed to a lack of effective regulation and a weak enforcement capacity existing in these countries, with an increase in this trade resulting from the growing size and sophistication of drug counterfeiters. In addition, due to both cost and lack of availability of medicines, consumers in developing countries are more likely to seek out these inexpensive options. The World Health Organization is mindful of the impact of counterfeit drugs on consumer confidence in health care systems, health professionals, the supply chain, and genuine suppliers of medicines and medical devices. Antibiotics, antituberculosis drugs, and antimalarial and antiretroviral drugs are frequently targeted, with reports of 60% of the anti-infective drugs in Asia and Africa containing active pharmaceutical ingredients outside their pharmacopoeial limits. This has obvious public health implications of increasing drug resistance and negating all the efforts that have already gone into the provision of medicines to treat these life threatening conditions in the developing world. This review, while focusing on counterfeit medicines and medical devices in developing countries, will present information on their impact and how these issues can be addressed by regulation and control of the supply chain using technology appropriate to the developing world. The complexity of the problem will also be highlighted in terms of the definition of counterfeit and substandard medicines, including gray pharmaceuticals. Although this issue presents as a global public health problem, outcomes in developing countries where counterfeit drugs to treat malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome not only result in drug resistance, but a number of deaths from the untreated disease, is in stark contrast with the developed world, where lifestyle drugs such as sildenafil (Viagra?) are most commonly counterfeited.
机译:世界卫生组织报告说,假冒药品可能占全球药品市场的50%以上,其中很大一部分是在发展中国家遇到的假冒药品。这种情况的发生是由于这些国家缺乏有效的监管和执法能力较弱,而这种交易的增加是由于假冒伪劣药品的规模和技术水平的提高。另外,由于成本和药品供应的不足,发展中国家的消费者更有可能寻求这些廉价的选择。世界卫生组织意识到假冒药品对消费者对卫生保健系统,卫生专业人员,供应链以及药品和医疗器械的真正供应商的信心的影响。抗生素,抗结核药以及抗疟和抗逆转录病毒药物经常成为攻击目标,据报道,亚洲和非洲有60%的抗感染药含有超出其药典范围的活性药物成分。这显然对公众健康产生影响,即增加耐药性并否定已经提供药物来治疗发展中国家这些威胁生命的疾病的所有努力。这篇综述着重于发展中国家的假药和医疗器械,同时将介绍有关其影响以及如何通过使用适合发展中国家的技术对供应链进行监管来解决这些问题的信息。问题的复杂性也将根据假药和不合格药品(包括灰色药品)的定义来强调。尽管此问题是一个全球性的公共卫生问题,但在发展中国家治疗疟疾,结核病和人类免疫缺陷病毒/后天免疫缺陷综合症的假冒药物不仅导致耐药性而且还会导致大量未经治疗的疾病导致死亡与发达世界形成鲜明对比的是,在世界上,假冒西地那非(Viagra ?)等生活方式药物最常见。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号